Business Description
Genscript Biotech Corp
NAICS : 541714
SIC : 8731
ISIN : KYG3825B1059
Share Class Description:
GNNSF: Class HTotal Employee Number:
6,165Compare
Compare
Traded in other countries / regions
01548.Hong KongG51.GermanyGNNSF.USA IPO Date
2017-07-24Description
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.14 | |||||
Equity-to-Asset | 0.82 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | -0.68 | |||||
Interest Coverage | 15.18 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 3.08 | |||||
Beneish M-Score | -3.07 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 13.6 | |||||
3-Year EBITDA Growth Rate | -0.8 | |||||
3-Year EPS without NRI Growth Rate | 0.9 | |||||
3-Year Book Growth Rate | 55.8 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 39.2 | |||||
9-Day RSI | 43.06 | |||||
14-Day RSI | 46.44 | |||||
3-1 Month Momentum % | 12.68 | |||||
6-1 Month Momentum % | -13.04 | |||||
12-1 Month Momentum % | -27.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.5 | |||||
Quick Ratio | 1.44 | |||||
Cash Ratio | 1.13 | |||||
Days Inventory | 32.74 | |||||
Days Sales Outstanding | 46.39 | |||||
Days Payable | 35.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.1 | |||||
Shareholder Yield % | 1.68 |
Profitability Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 57.67 | |||||
Operating Margin % | 27.36 | |||||
Net Margin % | -55.29 | |||||
EBITDA Margin % | -39.29 | |||||
FCF Margin % | 25.19 | |||||
OCF Margin % | 33.93 | |||||
ROE % | -12.56 | |||||
ROA % | -10.25 | |||||
ROIC % | 5.63 | |||||
3-Year ROIIC % | 21.39 | |||||
ROC (Joel Greenblatt) % | -74 | |||||
ROCE % | -10.07 | |||||
Years of Profitability over Past 10-Year | 4 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 78.41 | |||||
Shiller PE Ratio | 27.66 | |||||
PS Ratio | 3.97 | |||||
PB Ratio | 0.97 | |||||
Price-to-Tangible-Book | 0.97 | |||||
Price-to-Free-Cash-Flow | 15.59 | |||||
Price-to-Operating-Cash-Flow | 11.62 | |||||
EV-to-EBIT | -7.21 | |||||
EV-to-Forward-EBIT | 49.3 | |||||
EV-to-EBITDA | -8.63 | |||||
EV-to-Forward-EBITDA | 31.06 | |||||
EV-to-Revenue | 3.39 | |||||
EV-to-Forward-Revenue | 5.83 | |||||
EV-to-FCF | 13.43 | |||||
Price-to-GF-Value | 0.65 | |||||
Price-to-Projected-FCF | 5.52 | |||||
Price-to-Median-PS-Value | 0.4 | |||||
| Price-to-Net-Current-Asset-Value | 20 | |||||
Earnings Yield (Greenblatt) % | -13.87 | |||||
FCF Yield % | 6.37 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:GNNSF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Genscript Biotech Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 959.526 | ||
| EPS (TTM) ($) | -0.256 | ||
| Beta | 1.2532 | ||
| 3-Year Sharpe Ratio | 0.13 | ||
| 3-Year Sortino Ratio | 0.24 | ||
| Volatility % | 67.96 | ||
| 14-Day RSI | 46.44 | ||
| 14-Day ATR ($) | 0.011121 | ||
| 20-Day SMA ($) | 1.6 | ||
| 12-1 Month Momentum % | -27.27 | ||
| 52-Week Range ($) | 1.3 - 2.42 | ||
| Shares Outstanding (Mil) | 2,184.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Genscript Biotech Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Genscript Biotech Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-08-18 04:45 | In 46 days | ||
| Second quarter earnings results for 2026 | 2026-08-18 | In 45 days | ||
| First quarter earnings results for 2026 | 2026-07-08 | In 4 days | ||
| General meeting for 2026 | 2026-06-05 09:30 | 1.60 (+0.00%) | ||
| Annual report for 2025 | 2026-04-13 | 1.42 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-16 04:45 | 1.55 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-16 | 1.55 (+0.00%) | ||
| Second quarter earnings conference call for 2025 | 2025-08-18 04:45 | 2.19 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-18 | 2.19 (+0.00%) | ||
| General meeting for 2025 | 2025-05-29 14:00 | 1.36 (+0.00%) |
Show
Entries
Genscript Biotech Corp Frequently Asked Questions
What is Genscript Biotech Corp(GNNSF)'s stock price today?
The current price of GNNSF is $1.60. The 52 week high of GNNSF is $2.42 and 52 week low is $1.30.
When is next earnings date of Genscript Biotech Corp(GNNSF)?
The next earnings date of Genscript Biotech Corp(GNNSF) is 2026-07-08 Est..
Does Genscript Biotech Corp(GNNSF) pay dividends? If so, how much?
Genscript Biotech Corp(GNNSF) does not pay dividend.
Guru Commentaries on OTCPK:GNNSF
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| GenScript Debuts Industry's Highest Throughput DNA Synthesis Platform for Commercial DNA Digital Data Storage | 2022-04-13 |
Articles on Genscript Biotech Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers